Biological
FYB206
FYB206 is a biological therapy with 2 clinical trials. Currently 1 active trials ongoing.
Total Trials
2
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Completion Rate
0%(0/1)
Active Trials
1(50%)
Terminated
1(50%)
Phase Distribution
Ph phase_1
1
50%
Ph phase_3
1
50%
Phase Distribution
1
Early Stage
0
Mid Stage
1
Late Stage
Phase Distribution2 total trials
Phase 1Safety & dosage
1(50.0%)
Phase 3Large-scale testing
1(50.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
0.0%
0 of 1 finished
Non-Completion Rate
100.0%
1 ended early
Currently Active
1
trials recruiting
Total Trials
2
all time
Status Distribution
Active(1)
Terminated(1)
Detailed Status
Active, not recruiting1
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
2
Active
1
Success Rate
0.0%
Most Advanced
Phase 3
Trials by Phase
Phase 11 (50.0%)
Phase 31 (50.0%)
Trials by Status
active_not_recruiting150%
terminated150%
Recent Activity
1 active trials
Showing 2 of 2
active_not_recruitingphase_1
Assessment of PK Similarity of FYB206 in Comparison With Keytruda in Resected Stage II or III Melanoma Patients
NCT06551064
terminatedphase_3
Similar Efficacy, Safety, and Immunogenicity of FYB206 in Comparison to Keytruda as add-on to Chemotherapy in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC)
NCT06643117
Clinical Trials (2)
Showing 2 of 2 trials
NCT06551064Phase 1
Assessment of PK Similarity of FYB206 in Comparison With Keytruda in Resected Stage II or III Melanoma Patients
NCT06643117Phase 3
Similar Efficacy, Safety, and Immunogenicity of FYB206 in Comparison to Keytruda as add-on to Chemotherapy in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC)
All 2 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 2